Verrica Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for dermatological conditions. The company's lead product candidate, VP-102, is a proprietary topical therapy for the treatment of molluscum contagiosum, a highly contagious viral skin infection that primarily affects children. VP-102 is currently in Phase 3 clinical development and has the potential to be the first FDA-approved treatment for molluscum contagiosum. Verrica is also developing therapies for other dermatological conditions, including common warts and external genital warts.